{"id":484520,"date":"2021-04-29T09:06:40","date_gmt":"2021-04-29T13:06:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/brainsway-announces-launch-of-noninvasive-treatment-for-smoking-addiction-to-u-s-providers\/"},"modified":"2021-04-29T09:06:40","modified_gmt":"2021-04-29T13:06:40","slug":"brainsway-announces-launch-of-noninvasive-treatment-for-smoking-addiction-to-u-s-providers","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/brainsway-announces-launch-of-noninvasive-treatment-for-smoking-addiction-to-u-s-providers\/","title":{"rendered":"BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers"},"content":{"rendered":"

\nPatients in areas across the country now have access to Deep Transcranial Magnetic Stimulation (Deep TMS) therapy as an aid for short-term smoking cessation
\n<\/h2>\n
\n

CRESSKILL, N.J. and JERUSALEM, April 29, 2021 (GLOBE NEWSWIRE) — BrainsWay Ltd<\/u><\/a>. (NASDAQ & TASE: BWAY) (\u201cBrainsWay\u201d or the \u201cCompany\u201d), a global leader in advanced noninvasive treatment of brain disorders, today announced the distribution of its first 10 Deep Transcranial Magnetic Stimulation (Deep TMS) devices for smoking addiction to practices across the United States. The recently FDA-cleared aid for short-term smoking cessation<\/u><\/a> offers a noninvasive treatment that administers electromagnetic pulses using BrainsWay\u2019s patented H4-coil through a cushioned helmet, stimulating neurons in brain structures associated with addiction.<\/p>\n

\u201cTobacco smoking is one of the leading causes of preventable disease and death throughout the world,\u201d said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. \u201cWe have seen lives drastically changed after undergoing Deep TMS treatment and are eager to bring this same hope to those who desire to quit smoking. Research shows that there is often comorbidity between tobacco use and mental disorders, and the COVID-19 pandemic has exacerbated both. Many patients have given up trying to quit, but now, with a noninvasive option like Deep TMS, we are hopeful they are able to take that step.\u201d<\/p>\n

Deep TMS is the first FDA-cleared noninvasive treatment in the addiction space for any TMS device, and currently serves as the only TMS platform technology with clinical outcome data for multiple brain disorders. In 2019, a double-blind, sham-controlled, multicenter randomized controlled trial <\/u><\/a>of 262 patients found Deep TMS to be an effective treatment, significantly improving the continuous quit rate, as well as reducing craving and the average number of cigarettes smoked per week. Participants in the study were highly addicted to smoking with a history of smoking an average of over 26 years and multiple failed attempts to quit.<\/p>\n

Deep TMS treatment for smoking addiction is currently available at the following clinics:<\/p>\n